27 May 2021 | News
Investment to support advancement of Ada’s symptom assessment and care navigation platform
Image Credit: shutterstock.com
Leaps by Bayer, the impact investment arm of Bayer, has led a $90 million Series B investment in Berlin-based digital health company Ada Health (Ada). Additional investors joined the round, including Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.
The investment will help advance Ada’s popular health assessment technology, enabling the digital health pioneer to accelerate its path towards becoming the world's leading personalised operating system for health, as well as to further grow the company’s leading position in the US.
In addition, Bayer and Ada Health are in discussions about entering into a longer-term strategic partnership to support the company’s healthcare businesses.
Ada Health has developed a powerful AI-based health assessment and care navigation platform that helps users to understand their symptoms, identify and differentiate conditions with a high degree of medical accuracy, and navigate safely to the right care, at the right time. Ada’s consumer app has become the world’s most popular and highest-rated symptom assessment app, with over 23 million assessments completed since its global launch.
Ada’s core technology is also available in a suite of AI-driven enterprise solutions. The company is collaborating with a range of leading health systems, insurers, life sciences companies, and global non-profit organisations to integrate its symptom assessment and care navigation solutions into a range of digital care journeys to improve outcomes for patients, consumers and healthcare providers.